Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas: Hoosier Oncology Group GI06-101

NCT00532441 is registered in ClinicalTrials.gov with Gabi Chiorean, MD as lead sponsor.

NCT NCT00532441
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00532441 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas: Hoosier Oncology Group GI06-101
Lead sponsor
Gabi Chiorean, MD
Phase
Phase 2
Overall status
Terminated
Start date
September 30, 2007
Completion date
August 31, 2010
Enrollment
25 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma